MX349294B - Formulaciones virales liofilizadas. - Google Patents
Formulaciones virales liofilizadas.Info
- Publication number
- MX349294B MX349294B MX2013006169A MX2013006169A MX349294B MX 349294 B MX349294 B MX 349294B MX 2013006169 A MX2013006169 A MX 2013006169A MX 2013006169 A MX2013006169 A MX 2013006169A MX 349294 B MX349294 B MX 349294B
- Authority
- MX
- Mexico
- Prior art keywords
- formulations
- lyophilized viral
- viral formulations
- lyophilized
- storage
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 230000003612 virological effect Effects 0.000 title abstract 4
- 241000700605 Viruses Species 0.000 abstract 4
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/765—Reovirus; Rotavirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41902010P | 2010-12-02 | 2010-12-02 | |
| PCT/US2011/063037 WO2012075376A2 (en) | 2010-12-02 | 2011-12-02 | Lyophilized viral formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013006169A MX2013006169A (es) | 2013-10-28 |
| MX349294B true MX349294B (es) | 2017-07-21 |
Family
ID=46162458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013006169A MX349294B (es) | 2010-12-02 | 2011-12-02 | Formulaciones virales liofilizadas. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9044498B2 (enExample) |
| EP (1) | EP2646052B1 (enExample) |
| JP (3) | JP6034797B2 (enExample) |
| KR (1) | KR102023207B1 (enExample) |
| CN (1) | CN103269716B (enExample) |
| AU (1) | AU2011336410B2 (enExample) |
| CA (1) | CA2819236A1 (enExample) |
| DK (1) | DK2646052T3 (enExample) |
| EA (1) | EA201390812A1 (enExample) |
| ES (1) | ES2630012T3 (enExample) |
| IL (1) | IL226646B (enExample) |
| MX (1) | MX349294B (enExample) |
| SG (1) | SG190419A1 (enExample) |
| TW (1) | TW201233803A (enExample) |
| WO (1) | WO2012075376A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG191602A1 (en) * | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| EP2646051A4 (en) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | FORMULATIONS OF LIQUID VIRUSES |
| MX349294B (es) | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| AU2012248082B2 (en) * | 2011-04-29 | 2015-08-20 | Oncolytics Biotech Inc. | Methods of purifying viruses using gel permeation chromatography |
| US11273127B2 (en) | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
| GB201513010D0 (en) * | 2015-07-23 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel formulation |
| BR112019009113A2 (pt) | 2016-11-04 | 2019-07-16 | Baxalta Incorporated | formulações de vírus adenoassociado |
| MY209364A (en) * | 2017-10-16 | 2025-07-03 | Serum Institute Of India Pvt Ltd | Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof |
| KR20210032984A (ko) | 2018-07-11 | 2021-03-25 | 박스알타 인코퍼레이티드 | Aav 조성물 |
| CN110279693B (zh) * | 2019-07-25 | 2021-06-15 | 军事科学院军事医学研究院微生物流行病研究所 | 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用 |
| CN112107678B (zh) * | 2020-09-30 | 2022-11-18 | 辰欣药业股份有限公司 | 一种含有胸腺法新的冻干组合物及其制备方法 |
| CN116270500B (zh) * | 2021-12-30 | 2025-05-06 | 安徽贝金基因科技有限公司 | 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用 |
Family Cites Families (106)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2505657A1 (fr) * | 1981-05-13 | 1982-11-19 | Pasteur Institut | Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5626851A (en) | 1987-11-30 | 1997-05-06 | The Wistar Institute Of Anatomy And Biology | Rotavirus reassortant vaccine |
| US5096885A (en) | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
| EP0410207B1 (en) | 1989-07-24 | 1997-01-22 | Bayer Corporation | Stabilization of highly purified proteins |
| AU673827B2 (en) | 1992-03-24 | 1996-11-28 | United Cancer Research Institute | Vaccine containing live virus for therapy of viral diseases and malignancies |
| CA2075521C (en) * | 1992-05-05 | 1995-11-28 | Kuniaki Koyama | Stabilized live vaccine |
| EP0728195A1 (en) | 1993-10-12 | 1996-08-28 | Chiron Corporation | Methods for preserving recombinant viruses |
| ATE328068T1 (de) | 1994-05-16 | 2006-06-15 | Merck & Co Inc | Papillomavirus vakzine |
| WO1996001651A1 (en) | 1994-07-11 | 1996-01-25 | The Government Of The United States Of America, Represented By The Department Of Health And Human Services | Attenuated human rotavirus vaccine |
| US6586006B2 (en) | 1994-08-04 | 2003-07-01 | Elan Drug Delivery Limited | Solid delivery systems for controlled release of molecules incorporated therein and methods of making same |
| US6290991B1 (en) | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6165773A (en) | 1995-10-25 | 2000-12-26 | Provalis Uk Limited | Methods of preserving viruses |
| GB9521806D0 (en) | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Preservation methods |
| FR2742756B1 (fr) | 1995-12-22 | 1998-04-03 | Pasteur Merieux Serums Vacc | Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation |
| FR2751343B1 (fr) * | 1996-07-16 | 1998-12-18 | Transgene Sa | Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament |
| WO1998013065A1 (en) | 1996-09-26 | 1998-04-02 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US5932223A (en) * | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6403098B1 (en) | 1996-09-26 | 2002-06-11 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US6616931B1 (en) | 1996-09-26 | 2003-09-09 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
| US20080261289A1 (en) | 1996-12-13 | 2008-10-23 | Schering-Plough Corporation | Compositions comprising viruses and methods for concentrating virus preparations |
| US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
| US6051238A (en) | 1996-12-20 | 2000-04-18 | Merck & Co., Inc. | Stabilizers for lyophilized mumps vaccines |
| CA2274755A1 (en) | 1996-12-20 | 1998-07-02 | Su-Pi Sheu | Stabilizers for lyophilized vaccines |
| US6290967B1 (en) * | 1996-12-20 | 2001-09-18 | Merck & Co., Inc. | Stabilizers for lyophilized vaccines |
| IL137510A0 (en) | 1998-02-17 | 2001-07-24 | Schering Corp | Compositions comprising viruses and methods for concentrating virus preparations |
| GB9808922D0 (en) * | 1998-04-24 | 1998-06-24 | Cantab Pharmaceuticals Res Ltd | Virus preparations |
| BRPI9912485B8 (pt) | 1998-07-28 | 2021-05-25 | The Government Of The Us Secretary Department Of Health And Human Services | composição imunogênica multivalente |
| CN1062770C (zh) * | 1998-11-12 | 2001-03-07 | 卫生部长春生物制品研究所 | 甲肝-麻疹二联疫苗及其生产方法 |
| DK1133316T3 (da) | 1998-11-16 | 2009-05-25 | Introgen Therapeutics Inc | Adenovirus-formulering til genterapi |
| US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
| US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
| AU4188100A (en) | 1999-04-08 | 2000-11-14 | Gregory M. Glenn | Dry formulation for transcutaneous immunization |
| US6592869B2 (en) | 1999-08-24 | 2003-07-15 | Teva Pharmaceutical Industries, Ltd. | Vaccine composition and method of using the same |
| IL148247A0 (en) | 1999-08-24 | 2002-09-12 | Teva Pharma | A vaccine composition and method of using the same |
| NZ518401A (en) | 1999-10-29 | 2004-01-30 | Nektar Therapeutics | Dry powder compositions having improved dispersivity |
| US7456009B2 (en) * | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| JP5118798B2 (ja) * | 2000-03-07 | 2013-01-16 | メルク・シャープ・エンド・ドーム・コーポレイション | アデノウイルス製剤 |
| US20020120228A1 (en) | 2000-06-08 | 2002-08-29 | Yuh-Fun Maa | Powder compositions |
| JP2003535119A (ja) | 2000-06-08 | 2003-11-25 | パウダージェクト ワクチンズ，インコーポレーテッド | 粉末組成物 |
| TWI289158B (en) | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
| GB0020089D0 (en) | 2000-08-15 | 2000-10-04 | Smithkline Beecham Biolog | Vaccine Composition |
| JP5063852B2 (ja) | 2000-09-25 | 2012-10-31 | ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング | 生ワクチン及び製造方法 |
| US20040033239A1 (en) | 2001-03-06 | 2004-02-19 | Evans Robert K | Adenovirus formulations |
| IL157304A0 (en) | 2001-03-16 | 2004-02-19 | Oncolytics Biotech Inc | Method of extracting virus from cell culture |
| WO2002101412A2 (en) | 2001-06-08 | 2002-12-19 | Powderject Vaccines, Inc. | Spray freeze-dried compositions |
| GB0124710D0 (en) | 2001-10-15 | 2001-12-05 | Quadrant Healthcare Uk Ltd | Therapeutic composition |
| AU2002346424A1 (en) | 2001-11-19 | 2003-06-10 | Becton, Dickinson And Company | Pharmaceutical compositions in particulate form |
| CA2469623C (en) | 2001-12-12 | 2012-05-29 | F H Faulding & Co Limited | Composition for the preservation of viruses |
| US20030153065A1 (en) | 2002-01-14 | 2003-08-14 | Genvec, Inc. | Composition and method for maintaining non-enveloped viral vectors |
| AR038153A1 (es) | 2002-01-18 | 2004-12-29 | Schering Ag | Formulaciones estabilizadas de adenovirus |
| US7923029B2 (en) | 2002-04-11 | 2011-04-12 | Medimmune Llc | Spray freeze dry of compositions for pulmonary administration |
| WO2003087327A2 (en) | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by freeze dried foam |
| US20040042972A1 (en) | 2002-04-11 | 2004-03-04 | Medimmune Vaccines, Inc. | Spray freeze dry of compositions for intranasal administration |
| DE60327069D1 (de) | 2002-04-30 | 2009-05-20 | Oncolytics Biotech Inc | Verbesserte reinigungsmethode für viren |
| CA2503946C (en) | 2002-11-01 | 2016-08-16 | Glaxosmithkline Biologicals S.A. | Drying process |
| US6752740B2 (en) | 2002-11-12 | 2004-06-22 | Jeffery T. Semmes | Continuously variable transmission |
| CN1745170A (zh) | 2002-12-17 | 2006-03-08 | 米迪缪尼疫苗股份有限公司 | 生物活性材料的高压喷雾干燥 |
| US6931888B2 (en) | 2003-02-07 | 2005-08-23 | Ferro Corporation | Lyophilization method and apparatus for producing particles |
| ES2529736T3 (es) | 2003-04-10 | 2015-02-25 | Novartis Vaccines And Diagnostics, Inc. | Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS |
| WO2005021033A2 (en) * | 2003-09-02 | 2005-03-10 | Glaxosmithkline Biologicals S.A. | Vaccine |
| WO2005052116A2 (en) | 2003-11-19 | 2005-06-09 | Merck & Co., Inc. | Preservative-containing virus formulations |
| EP1701738B1 (en) | 2003-12-17 | 2015-03-11 | Wyeth LLC | Method for producing storage stable RSV compositions |
| WO2005066333A1 (en) | 2003-12-30 | 2005-07-21 | Aventis Pasteur, Inc. | Stabilizing compositions for recombinant viruses |
| GB0404586D0 (en) | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
| BRPI0509117A (pt) | 2004-03-04 | 2007-08-28 | Wyeth Corp | método de liofilização para melhorar a cristalização de excipientes |
| EP1750760B1 (en) | 2004-06-02 | 2017-06-28 | Universal Stabilization Technologies, Inc. | Preservation by vaporization |
| WO2006029467A1 (en) | 2004-09-16 | 2006-03-23 | Btf Pty Ltd | Rapid freeze drying process |
| TW200626177A (en) | 2004-09-28 | 2006-08-01 | Alza Corp | Method and formulation for stabilizing alum-adsorbed vaccines |
| US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| KR101400379B1 (ko) * | 2004-11-05 | 2014-05-28 | 웰스테트 바이올로직스 코포레이션 | 안정하고 여과 가능한 외피보유 바이러스 조성물 |
| EP1833385B1 (en) | 2004-12-09 | 2008-08-27 | Precimed S.A. | Surgical tool holder for facilitated sterilization |
| US20060141483A1 (en) * | 2004-12-23 | 2006-06-29 | Calton Gary J | Stabilization of viral compositions |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| EP1954308B1 (en) * | 2005-09-16 | 2011-09-07 | Merial Ltd. | Stabilizers for freeze-dried vaccines |
| CN1765181A (zh) | 2005-10-19 | 2006-05-03 | 路兴波 | 高效抗病毒制剂 |
| US7875446B2 (en) | 2006-04-20 | 2011-01-25 | Wyeth Llc | Purification processes for isolating purified vesicular stomatitis virus from cell culture |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| EP1854478A1 (en) | 2006-05-12 | 2007-11-14 | Cytos Biotechnology AG | Nicotine-carrier vaccine formulation |
| EP1878791A1 (en) | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
| DK2055311T3 (en) | 2006-08-07 | 2017-07-24 | The Chemo-Sero-Therapeutic Res Inst | METHOD OF MANUFACTURING LIVING COPPER VACCINE |
| US20100129379A1 (en) | 2006-09-25 | 2010-05-27 | John Carpenter | Stabilized antibody formulations and uses thereof |
| DK2099485T3 (en) | 2006-11-03 | 2018-05-22 | Alphavax Inc | Alphavirus and alphavirus replica particle formulations and associated methods |
| MX2009004862A (es) * | 2006-11-07 | 2009-07-17 | Sanofi Pasteur Biologics Co | Estabilizacion de vacunas por liofilizacion. |
| CA2674026C (en) | 2006-12-27 | 2018-08-21 | Pfizer Products Inc. | Methods of vaccine administration |
| WO2008106646A2 (en) | 2007-03-01 | 2008-09-04 | Introgen Therapeutics, Inc | Methods and formulations for topical gene therapy |
| SG191602A1 (en) * | 2007-03-12 | 2013-07-31 | Oncolytics Biotech Inc | Reoviruses having modified sequences |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| CA2681567C (en) * | 2007-03-22 | 2016-07-19 | The Regents Of The University Of Colorado, A Body Corporate | Method of preparing an immunologically-active adjuvant-bound dried vaccine composition |
| WO2009014774A1 (en) | 2007-04-06 | 2009-01-29 | Inviragen, Inc. | Methods and compositions for live attenuated viruses |
| TW200909581A (en) | 2007-05-21 | 2009-03-01 | Oncolytics Biotech Inc | Mutant reoviruses and methods of making and using |
| WO2009042202A2 (en) | 2007-09-25 | 2009-04-02 | Aridis Pharmaceuticals | Formulations for preservation of rota virus |
| JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| WO2009056651A1 (en) | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
| JP4932940B2 (ja) | 2007-11-12 | 2012-05-16 | セラクローン サイエンシーズ， インコーポレイテッド | インフルエンザの治療および診断のための組成物および方法 |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| WO2009108689A1 (en) * | 2008-02-25 | 2009-09-03 | Novavax, Inc. | Sugar glassified virus like particles (vlps) |
| LT2805731T (lt) * | 2009-09-03 | 2019-02-11 | Ablynx N.V. | Stabilios polipeptidų kompozicijos ir jų panaudojimas |
| EP2646051A4 (en) * | 2010-12-02 | 2014-05-28 | Oncolytics Biotech Inc | FORMULATIONS OF LIQUID VIRUSES |
| MX349294B (es) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| AU2012248082B2 (en) * | 2011-04-29 | 2015-08-20 | Oncolytics Biotech Inc. | Methods of purifying viruses using gel permeation chromatography |
| JP6065096B2 (ja) | 2015-12-25 | 2017-01-25 | ダイキン工業株式会社 | 調湿装置 |
-
2011
- 2011-12-02 MX MX2013006169A patent/MX349294B/es active IP Right Grant
- 2011-12-02 JP JP2013542199A patent/JP6034797B2/ja active Active
- 2011-12-02 CN CN201180062149.7A patent/CN103269716B/zh active Active
- 2011-12-02 EP EP11845053.5A patent/EP2646052B1/en active Active
- 2011-12-02 SG SG2013040811A patent/SG190419A1/en unknown
- 2011-12-02 TW TW100144335A patent/TW201233803A/zh unknown
- 2011-12-02 AU AU2011336410A patent/AU2011336410B2/en active Active
- 2011-12-02 EA EA201390812A patent/EA201390812A1/ru unknown
- 2011-12-02 KR KR1020137016720A patent/KR102023207B1/ko active Active
- 2011-12-02 ES ES11845053.5T patent/ES2630012T3/es active Active
- 2011-12-02 WO PCT/US2011/063037 patent/WO2012075376A2/en not_active Ceased
- 2011-12-02 US US13/309,901 patent/US9044498B2/en active Active
- 2011-12-02 CA CA2819236A patent/CA2819236A1/en active Pending
- 2011-12-02 DK DK11845053.5T patent/DK2646052T3/en active
-
2013
- 2013-05-29 IL IL226646A patent/IL226646B/en active IP Right Grant
-
2015
- 2015-04-22 US US14/693,100 patent/US9610352B2/en active Active
-
2016
- 2016-09-01 JP JP2016170628A patent/JP6433954B2/ja active Active
-
2018
- 2018-08-17 JP JP2018153546A patent/JP2018172443A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| SG190419A1 (en) | 2013-06-28 |
| AU2011336410A1 (en) | 2013-03-28 |
| EP2646052B1 (en) | 2017-03-29 |
| EP2646052A4 (en) | 2014-01-08 |
| WO2012075376A3 (en) | 2012-08-16 |
| JP2016199591A (ja) | 2016-12-01 |
| JP6433954B2 (ja) | 2018-12-05 |
| MX2013006169A (es) | 2013-10-28 |
| CN103269716B (zh) | 2015-05-27 |
| US9044498B2 (en) | 2015-06-02 |
| CA2819236A1 (en) | 2012-06-07 |
| EP2646052A2 (en) | 2013-10-09 |
| JP6034797B2 (ja) | 2016-11-30 |
| KR20140014096A (ko) | 2014-02-05 |
| EA201390812A1 (ru) | 2013-11-29 |
| WO2012075376A2 (en) | 2012-06-07 |
| TW201233803A (en) | 2012-08-16 |
| US20150224198A1 (en) | 2015-08-13 |
| ES2630012T3 (es) | 2017-08-17 |
| JP2018172443A (ja) | 2018-11-08 |
| US20120141528A1 (en) | 2012-06-07 |
| IL226646B (en) | 2018-02-28 |
| KR102023207B1 (ko) | 2019-11-25 |
| AU2011336410B2 (en) | 2015-01-22 |
| DK2646052T3 (en) | 2017-07-17 |
| US9610352B2 (en) | 2017-04-04 |
| CN103269716A (zh) | 2013-08-28 |
| JP2013544288A (ja) | 2013-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX349294B (es) | Formulaciones virales liofilizadas. | |
| WO2012075379A3 (en) | Liquid viral formulations | |
| MX2021006342A (es) | Mutantes de virus de influenza y usos para los mismos. | |
| CA2817005A1 (en) | Rabies glycoprotein virus-like particles (vlps) | |
| PH12018501602A1 (en) | Subunit immersion vaccines for fish | |
| IN2014MN01548A (enExample) | ||
| MX2009010549A (es) | Virus atenuados utiles para vacunas. | |
| EA201391515A1 (ru) | Инактивированная вакцина вируса денге | |
| MX2012008221A (es) | Inhibidores de virus flaviviridae. | |
| MX337936B (es) | Compuestos inhibidores del virus de la hepatitis c. | |
| EA201190327A1 (ru) | Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv | |
| MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
| WO2011082388A3 (en) | Infectious dna vaccines against chikungunya virus | |
| IN2015DN02546A (enExample) | ||
| MX339731B (es) | Vacunas contra la bronquitis infecciosa derivadas de cepas similares a qx-bi. | |
| MX2013003245A (es) | Vacuna contra virus de diarrea viral de bovinos. | |
| WO2014008475A3 (en) | Compositions and methods related to viral vaccines | |
| MA35303B1 (fr) | Vaccin contre la rhinite equine | |
| GB201008123D0 (en) | Novel compounds | |
| WO2012003030A3 (en) | Methods of identifying & using anti-viral compounds | |
| MX2012002702A (es) | Vacuna de herpesvirus bovino. | |
| MX2023011129A (es) | Mutantes del virus de la influenza b y usos de los mismos. | |
| BRPI0819031A2 (pt) | processo para preparar cepas virais atenuadas, vírus atenuado, uso de uma cepa viral atenuada e vacina baseada em vírus atenuado vivos. | |
| BR112012021650A2 (pt) | "parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção de um parvovírus recombinante, e, uso de uma vacina." | |
| MX2010003505A (es) | Vacuna recombinante de vector viral inactivado. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |